EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, Christophe RICHEZ

Organisation/Company: CHU DE BORDEAUX

Country: France

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
09/2020-08/2021	ABBVIE	Expert Advice on JAK Inhibitors and RINVOQ®	rheumatoid arthritis, spondyloarthritis
03/2021-08/2021	ABBVIE	JAK Inhibitors and RINVOQ®	rheumatoid arthritis
09/2020-09/2020	LILLY	Ixekizumab Realization and writing of clinical situations on anti-IL17, in dematerialized form	Spondyloarthritis
12/2020-12/2020	LILLY	Baricitinib	lupus
01/2021-05/2021	PFIZER	Tofacitinib	rheumatoid arthritis
09/2019-09/2019	ONO PHARMA	Role of follicular T cells in autoimmune diseases	
08/2020-12/2020	ASTRA ZENECA	Anifrolumab	Systemic lupus erythematosus
06/2022-12/2022	ABBVIE	Meeting of experts, exchanges and discussions debate around spondyloarthritis	
06/2020-12/2020	MSD	News on chronic inflammatory rheumatism	
09/2019-11/2019	ASTRA ZENECA	Anifrolumab	Systemic lupus

10/2021-12/2021	ABBVIE	Participation in a meeting of experts on spondyloarthritis	
08/2019-09/2019	PFIZER	Tofacitinib (expertise on post-hoc data analysis of Tofacitinib)	rheumatoid arthritis
01/2022-(current)	ASTRA ZENECA	Anifrolumab and other lupus treatments	
01/2022-(current)	PFIZER	Tofacitinib	rheumatoid arthritis, data from oral survaillance
03/2022-(current)	PFIZER	Tofacitinib (improve understanding of the oral surveillance study methodology with tofacitinib)	rheumatoid arthritis
05/2022-(current)	NOVARTIS	Ianalumab (Identify medical needs, ways to optimize the Ianalumab phase 3 development plan)	lupus
05/2022-(current)	GSK	Inflammatory autoimmune pathologies	
03/2022-(current)	ABBVIE	"Real-world effectiveness and treatment patterns of UPadaciTInib in Monotherapy or Used in combination with Methotrexate In active Psoriatic Arthritis patients"	
06/2020-09/2020	BIOGEN	Writing of a digital training support on the current management of RICs (3h00) + Animation of the training (1h00 x 2) + Animation of the Q&A session (0h30 x 2)	
11/2021-11/2021	MSD	Understand the clinical needs of European and American physicians on LES	
06/2020-06/2020	AMGEN	Participation as an expert during the Amgen virtual Advisory Board on anti-TNFs and COVID- 19	
05/2021-05/2021	BIOGEN	What can we put in place in terms of medical education to improve the management of RIC patients by anti-TNF?	
12/2020-12/2020	ABBVIE	Upadacitinib molecule (Rinvoq)	spondyloarthritis
09/2019-09/2019	AMGEN	Intervention on "Combined tsDMARD and bDMARD therapy"	
02/2018-01/2020	GLENMARK PHARMACEUTICALS	Participation in a committee that will meet in the context of physical or virtual meetings, in France and in the United States, in order to discuss the further design of a study on systemic lupus	
06/2021-12/2021	ABBVIE	Upadacitinib (exchanges and discussions debate around Spondyloarthritis, and upadacitinib)	spondyloarthritis
07/2021-(current)	NOVARTIS	1/ Opinion on projects or studies; 2/ Training of Novartis headquarters and field medical teams on systemic lupus: the vision of the rheumatologist	
04/2021-04/2022	ABBVIE	Upadacitinib	Psoriatic arthritis
05/2022-05/2022	ASTRA ZENECA	Evusheld	Covid-19
06/2020-07/2020	ABBVIE	Participation as an expert during a 3-hour virtual Advisory Board on July 3, 2020	
10/2022-(current)	GSK	management of systemic lupus	
09/2022-(current)	Novartis	Management of rare systemic autoimmune diseases	
09/2022-(current)	Abbvie	Upadacitinib	rheumatoid arthritis

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
07/2017-(current)	CLUB RHUMATISMES ET INFLAMMATION CRI	President	
01/2019-(current)	FILIÈRE DES MALADIES AUTO-IMMUNES ET AUTO-INFLAMMATOIRES RARES FAI2R	Member of the steering committee and the scientific council	
09/2017-(current)	SOCIÉTÉ FRANÇAISE DE RHUMATOLOGIE	Board member	

2.4 Financial interests

Company	Financial Interest
Lilly	Lilly provides free baricitinib for the academic CRI-RA study for which I am the medical coordinator
Lilly	fees and honoraria
Biogen	Biogen provides low price adalimumab and placebo of adalimumab for the academic CRI-RA study for which I am the medical coordinator
Biogen	fees and honoraria
Astra Zeneca	fees, honoraria, travel and conference attendance
Abbvie	fees, honoraria, travel and conference attendance
Pfizer	fees and honoraria
Galapagos	fees and honoraria
Novartis	fees and honoraria
Amgen	fees and honoraria
GSK	fees and honoraria
MSD	fees and honoraria
Janssen	fees and honoraria
Celltrion	fees, honoraria, travel and conference attendance

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
09/2019-05/2022	Amgen	20170588	Lupus
09/2020-10/2021	Abbvie	M19-130	Lupus
10/2017-(current)	Astra-Zeneca	SPOCS	Lupus
12/2015-(current)	Astra-Zeneca	Anifrolumab	Lupus
11/2021-(current)	BMS	026-024	Lupus
05/2022-(current)	Biogen	230LE303 Topaz	lupus
07/2016-06/2021	Janssen	PsaBIO	psoriatic arthritis
01/2019-12/2020	Lilly	Baricitinib JAIA	Lupus

01/2020-(current)	Lilly	Baricitinib JAIM	Lupus
02/2020-(current)	Lilly	Baricitinib JAJA	Rheumatoid arthritis
03/2021-12/2021	Galapagos	GLIDER	Sjogren
05/2019-11/2020	GSK	OBSERVE	Lupus
09/2020-(current)	Fresenius Kabi	adalimumab	rheumatoid arthritis and spondyloarthritis
10/2017-06/2020	Janssen	ustekinumab PROUST	psoriatic arthritis
05/2019-(current)	Nordic-Pharma	all targeted treatments	rheumatoid arthritis and psoriatic arthritis
09/2021-(current)	UCB	SL0043	lupus

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2018-05/2022	Abbvie	Upadacitinib 16-098	rheumatoid arthritis
03/2021-(current)	Abbvie	Upadacitinib UPHOLD	rheumatoid arthritis
02/2022-(current)	Abbvie	Upadacitinib UPSTAND	spondyloarthritis
07/2019-(current)	Sandoz	etanercept (erelzi) BRONZE	inflammatory rheumatism
01/2019-09/2021	Lilly	Baricitinib I4V MC009 REAL	rheumatoid arthritis
07/2020-(current)	Lilly	PROSPIRIT	psoriatic arthritis

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Mylan/AbbVie/Sandoz/Biogen/UCB/Pfizer/MSD/Amgen	CLUB RHUMATISMES ET INFLAMMATION MISE À JOUR DES FICHES ANTI-TNF, ANTI-IL6 ET ANTI-IL17 Organisme financeur

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

Period	Products	Therapeutic Indication	Involvement in the repurposing
01/2020-(current)	metformine	Rheumatoid arthritis	Involvement in the repurposing of the medicinal product where my organisation is acting as the champion of the repurposing

2.10 Any other interests or facts

Medical coordinator of the academic PHRC clinical trial CRI-RA studying the combination of baricitinib + adalimumab versus baricitinib alone in refractory RA
Medical coordinator of the academic PHRC clinical trial METorMET2 studying the combination of methotrexate + metformine versus methotrexate alone in early RA
Member of the board of Société Française de Rhumatologie
President of the Club Rhumatismes et Inflammation

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Christophe Richez
Date:	2022-09-01

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template